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Because the decision-making capacity of individuals with
schizophrenia may fluctuate, additional protections for
such persons who enroll in long-term research studies
may be needed. For the NIMH-sponsored Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) schizo-
phrenia study, new procedures were developed to help ensure
an objective assessment of a patient’s continued participa-
tion in the study if decision-making capacity lapsed. Each
research participant had a subject advocate who could
recommend that the subject be withdrawn from the study
if capacity lapsed and continued participation was not in
the subject’s best interest. The main goals of the procedures
were to protect the interests of subjects and to prevent
unnecessary dropouts. We surveyed research personnel
regarding the effectiveness and implementation of the
procedures. Responses were received from 73 personnel
at 49 research sites, representing 70% of possible respond-
ents and 91% of eligible sites. A majority of respondents
were favorably disposed toward subject advocates, and
though most reported that the procedures had no discernible
effect on study recruitment, subject autonomy, or subject
retention, for those who reported an impact, it was almost
always positive. Some respondents reported that the proce-
dures helped by engaging family members and promoting
a positive view of schizophrenia research. A majority
thought that similar arrangements would be useful in future
longitudinal research studies. Nonspecific benefits included
good public relations and engagement of family members.
Improved training regarding the procedures may be needed
to achieve specific goals of enhanced patient autonomy and
retention in the study.
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An adequate level of decision-making capacity is neces-
sary to provide valid consent for participation in research
projects. For time-limited studies that will be completed
shortly after consent is obtained (e.g., a single blood draw
or diagnostic test), adequate capacity at the time that
consent is given is all that is necessary. But for longitu-
dinal studies involving participants with considerable po-
tential for fluctuating capacity, a method to address
diminished decision-making capacity in research partic-
ipants is desirable.1,2 One of the purposes of informed
consent is to facilitate research participants’ ability to
protect their own interests.3 If their underlying condition
worsens as a project proceeds, or if the study leads to un-
expected risks or discomforts, research participants have
the right to stop their participation or to renegotiate the
terms of their involvement. Without the capacity to rec-
ognize such changes in circumstances, participants may
lose the ability to protect their interests.
Although investigators may commonly withdraw sub-
jects when they believe that continued participation in
a research project would not be in their interests, inves-
tigators and subjects may have conflicting interests when
it comes to decisions about continuing in a study, making
it hard for the former to act objectively. In this context,
we developed a mechanism designed to promote the in-
dependent consideration of a subject’s interests.4
As we have discussed previously, the development of
a way to ensure that a research participant’s interests
are considered objectively has been hampered by the am-
biguous legal climate surrounding the assignment of
decision-making responsibility to third parties in research
settings.4,5 Few states now clearly permit surrogates to
make decisions about participation in research. In this ar-
ticle, we describe ‘‘subject advocate’’ procedures thatwere
developed to help protect the interests of research subjects
in a large, multiphase clinical trial. The procedures were
an attempt to use a third party in order to provide inde-
pendent input into the continued participation of a re-
search participant if the participant’s decision-making
capacity lapsed. The subject advocate, as defined in the
CATIE study, provided protection in amanner consistent
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with existing law. We present the results of an evaluation
of these procedures that was intended to determine the
effectiveness of the procedures in achieving their goals
and to identify possible problems and improvements.
Methods
The CATIE Schizophrenia Study
In the National Institute of Mental Health–sponsored
Clinical Antipsychotic Trials of Intervention Effective-
ness (CATIE) schizophrenia study, almost 1500 individ-
uals with schizophrenia were enrolled in a study with
a goal that required the long-term participation of
subjects.6 The goal of the study was to determine the
comparative long-term effectiveness of antipsychotic
drugs in ‘‘real-world’’ settings. Potential participants
were screened for decision-making capacity using the
MacArthur Competence Assessment Tool–Clinical
Research (MacCAT-CR) prior to randomization.7
CATIE subjects were asked to participate for 18 or
more months so that longer-term outcomes could be
assessed. In order to mimic usual treatment conditions,
the protocol allowed participants who discontinued study
treatments to receive subsequent study treatments. Upon
enrollment, all participants were randomly assigned to
double-blinded treatment with one of five antipsychotic
drugs. If a participant discontinued the assigned drug for
any reason, he or she entered a second phase of the study,
in which a second FDA-approved antipsychotic drug was
randomlyassigned.Ifaparticipantdiscontinuedthesecond
drug, the participant entered a third phase, in which one of
eight drug-treatment strategies was selected. One of the
study’s aims was to evaluate serial treatment strategies.
The Subject Advocate Role in CATIE
In some instances, it was expected that treatment discon-
tinuation would be accompanied by diminished decision-
making capacity. The role of ‘‘subject advocate’’ was
developed as a practical way to protect subjects while
helping the study achieve its scientific goals. Each poten-
tial study subject designated a subject advocate to partic-
ipate in the initial consent discussion and to assist with
decision making. If a family member or friend could
not serve as subject advocate, a person not otherwise
involved in the research (e.g., a social worker or case
manager) was selected to serve in this role.
The initial decision about enrollment in the study was
made by the subject, who had to have adequate decision-
making capacity to do so. Subsequently, if a subject’s
capacity lapsed to the point where the subject could no
longer protect his or her own interests, consultation with
the subject advocate was required. The subject advocate
could then recommend that the participant be withdrawn
from the study if the advocate determined that the original
risk/benefit ratio that led the subject to consent to par-
ticipation had changed substantially and adversely with
regard to the subject’s interests. However, the subject ad-
vocate could permit a subject whose decision-making ca-
pacity had lapsed to remain in the study if the risk/benefit
ratio had not been significantly and unfavorably altered
and if the subject continued to consent to participate.
The primary goal of the subject advocate was to ensure
that a research participant’s interests were protected in
the context of a multiphase clinical trial involving partic-
ipants with a significant potential for fluctuating decision-
making capacity. An important secondary goal was to
help the study achieve its aims, including the evaluation
of the effectiveness of serial treatment strategies for ‘‘real-
world’’ patients with schizophrenia, including those with
fluctuating decision-making capacity. By being available
to assess the subject’s interests through the study’s mul-
tiple phases, the subject advocate could ensure that sub-
jects were protected and that the study’s generalizability
would be enhanced.
Training for the subject advocate procedures was con-
ducted at an investigators’ meeting before subject recruit-
ment began. The training session was available online
throughout the conduct of the study. Inaddition, awritten
description of the subject advocate procedures was pro-
vided to all study personnel in the trial’s Study Reference
Manual. Personnel at the research sites were instructed to
provide a handout describing the purpose of the proce-
dures to potential subjects and subject advocates.
Evaluation of the Subject Advocate Procedures
To evaluate the implementation of subject advocate pro-
cedures, we conducted an anonymous online survey of re-
search personnel at CATIE research sites. We invited the
site’s principal investigator and a second member of each
site’s research staff who should have been familiar with
the subject advocate procedures to complete the survey.
Nomore than two individuals from a site were allowed to
respond to the questionnaire. Respondents provided in-
formation about their role in the project and answered
questions regarding their understanding of subject advo-
cate procedures, their interactions with subject advocates,
and their opinions regarding the value and success of the
procedures. We also sought to understand how institu-
tional review boards at the sites responded to the proce-
dures and solicited the respondents’ advice regarding how
the procedures could be improved. Procedures were ap-
proved by the Biomedical IRB at the University of North
Carolina at Chapel Hill.
Wethenconductedpen-and-paper surveysofa subsetof
subjects and subject advocates at the clinical research sites.
When subjects completed or left the study, we asked them
to complete a surveywith questions regarding their under-
standing of subject advocate procedures and their opin-
ions regarding the value and success of the procedures.
Sites also asked the subject advocates of participants
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leaving the study to complete a similar survey. Procedures
for this phase of the study were approved by the Biomed-
ical IRBat theUniversityofNorthCarolinaatChapelHill
and by the IRB at each of the participating research sites.
In this evaluation, we had no a priori hypotheses. We
present descriptive statistics that were used to help deter-
mine the effectiveness of the procedures in achieving their
goals, to demonstrate how the procedures were perceived
by individuals who implemented them and by others who
participated in the study, and to identify any problems
with the implementation of the procedures.
Results
We received valid responses from 73 research personnel
representing 70% of the 104 surveys distributed. Twenty-
two of the respondents were study principal investigators
(PIs), 40 were study coordinators, four were study re-
cruiters, and seven were other personnel. Responses
were received from at least one person at 49 of the 54
(91%) sites that were sent surveys.
We first sought to determine how well study personnel
understood the purpose of the subject advocate proce-
dures. All respondents identified either protection of sub-
jects or promotion of autonomy as a purpose of having
a subject advocate, but only 27% understood that im-
proved retention was a goal of the procedures.
All respondents understood that the subject advocate
had to be contacted if a participant had impaired deci-
sion-making capacity. All study coordinators and 91%
of study PIs understood that the subject advocate was
supposed to be present or contacted at the time the par-
ticipant consented to the study.
In practice, respondents also contacted subject advo-
cates in other circumstances. Fifteen percent of respond-
ents said it was helpful to contact subject advocates if the
participant was upset with research staff, and 31% said
this was helpful when the participant requested to leave
the study. Forty-three percent of respondents reported
that it was useful to contact subject advocates whenever
participants changed study phases (i.e., required a change
in antipsychotic medicines).
Eighty percent of responding sites reported that their
IRB(s) accepted the subject advocate procedures as pro-
posed without change. Two sites reported that their IRB
required the subject advocate to be present at each phase
change, and four sites did not allow other, non-research
personnel at the site to serve as subject advocate—instead,
only people not employed by the research institution
could serve in this role. Two sites were not allowed to con-
tact the subject advocates directly but instead had to have
the research participant make this contact. Seventy per-
cent of respondents agreed or strongly agreed that their
IRB thought the subject advocate procedures were
a good idea, 28% neither agreed nor disagreed, and
only one respondent (1%) disagreed with the statement.
Table 1 shows how research personnel perceived
the effectiveness of the subject advocate procedures in
achieving their main goals. Sixty percent of respondents
thought the procedures had no effect on retention of
subjects in the study, while 38% thought they were helpful
and one person (1%) thought they hindered retention.
Regarding subject autonomy, 37% of respondents
indicated that the subject advocate procedures had
Table 1. Study Personnel Views of Subject Advocate Procedures
(N = 73)
At your site, what effect did the subject advocate procedures have
on enrolling people in the study (i.e., recruitment)?
Greatly helped N = 2 3%
Somewhat helped 12 16%
Had no discernible effect 43 59%
Somewhat hindered 16 22%
Greatly hindered 0 0%
At your site, what effect did the subject advocate procedures
have on keeping subjects in the study (i.e., retention)?
Greatly helpful 3 4%
Somewhat helpful 25 34%
Had no discernible effect 44 60%
Somewhat hindered 1 1%
Greatly hindered 0 0%
At your site, what effect did the subject advocate procedures
have on the subject’s ability to make his or her own decisions
(i.e., autonomy)?
Very positive effect 2 3%
Somewhat positive effect 25 34%
No discernible effect 42 58%
Somewhat negative effect 4 5%
Very negative effect 0 0%
Overall, the effort required to obtain a subject advocate for
each subject was worthwhile.
Strongly agree 16 22%
Agree 33 45%
Neither agree nor disagree 14 19%
Disagree 10 14%
Strongly disagree 0 0%
Suggested improvements to subject advocate procedure
implementation*




Clearer indication of the subject advocate
purpose
35 48%
Clearer indication of times to contact
the subject advocate
33 45%




*Respondents could select all applicable responses.
(total responses = 150)
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a very or somewhat positive effect on subjects’ abilities to
make their owndecisions, while 58% thought therewas no
discernible effect and 5% thought there was a somewhat
negative effect on subject autonomy. The table also shows
that a majority of respondents agreed that the effort to
obtain subject advocates was worthwhile and thought
the procedures had no effect on subject recruitment. In
addition, the table summarizes the several ways that
respondents thought implementation of the subject advo-
cate procedures could be improved. Figure 1 shows that
respondents thought the procedures promoted a positive
view of the CATIE study among a variety of constituen-
cies. Figure 2 shows that considerably more than half of
respondents (62%) agreed or strongly agreed that subject
advocate procedures similar to those used in CATIE
should be used in all future studies involving persons
with schizophrenia. However, 11% of respondents dis-
agreed with this, and 5% disagreed strongly. The remain-
ing 22% were neutral.
We asked all survey respondents to provide any com-
ments they might have about the subject advocate pro-
cedures. The most common theme among the 31
comments provided concerned the difficulty of finding
family members or friends to serve as subject advocate.
Several respondents noted that many individuals in the
study did not have anyone to designate as subject advo-
cate, so site personnel had to identify someone to serve in
this role. Several commented that having family mem-
bers as subject advocate promoted more familial involve-
ment, which was positive for the participant and the
family member. There were mixed comments regarding
non-family-member subject advocates. At one site, ‘‘sev-
eral significant others’’ lost significance and had to be
replaced. Case manager turnover at one site caused a sim-
ilar problem. Sites that relied on non-research personnel
at the site to serve as subject advocate noted schedul-
ing difficulties. A site that used members of the local
National Alliance for the Mentally Ill (NAMI) chapter
noted that this promoted a positive view of research
by the NAMI members. Good public relations were
a consequence of the procedures noted by a few who
commented.
Surveys of Subjects and Subject Advocates
The phase of the study involving surveys of subjects and
subject advocates was implemented very late in the course
of the study. A convenience sample of 41 subjects and 24
subject advocates provided responses at 10 sites. Subject
advocates (42% were parents of subjects, 21% were
friends or other relatives, 33% were clinicians whose
patients or clients were enrolled in the study, and 4%
were someone else designated by the site) had a positive
view of their role. Seventy-six percent of advocates agreed
or strongly agreed that the procedures allowed research
participants greater freedom tomake their own decisions.
Seventy-nine percent agreed or strongly agreed with the
statement that serving as subject advocate improved their
opinion of schizophrenia research. No subject advocates
who responded agreed that serving as advocate was a bur-
den. Ninety-six percent agreed or strongly agreed that all
schizophrenia research should include ‘‘someone like
a CATIE subject advocate.’’
Subject respondents also had a favorable view of the
subject advocate mechanism. More than half of respond-
ents (54%) agreed that having the subject advocate pro-
cedures positively influenced their decision to participate
in the study. Thirty-two percent of respondents were
neutral, 7% disagreed, and 7% did not respond.
On the other hand, some study participants thought
the procedures interfered with their autonomy. Two peo-
ple (5%) strongly agreed and three (7%) agreed with the
statement ‘‘My subject advocate got in the way of my
ability to make my own decisions.’’ Most respondents,
however, disagreed (32%) or strongly disagreed (39%)
with this statement; 5% were neutral.
Discussion
In this evaluation, we learned that subject advocate pro-



















































Fig. 1. Percentage of research personnel who endorsed the view
that subject advocate procedures promoted a positive view of
the CATIE study among subjects, family members, advocacy
groups, IRB members, or the general community, or did not






Fig. 2. Subject advocate procedures similar to those used in
the CATIE study should be used in all future studies involving
persons with schizophrenia.
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Research personnel understood the purposes of subject
advocate procedures, but some viewed the advocate’s
role as broader than intended. Most respondents
thought the effort to obtain subject advocates was
worthwhile. A majority felt that such procedures should
be used in future longitudinal studies involving subjects
with schizophrenia, although a few strongly disagreed
with this.
It is less clear how successful the subject advocate pro-
cedures were in achieving the goals of helping to protect
the rights of research participants whose decision-making
capacity may have fluctuated, and of helping to retain
such subjects in the longitudinal trial. A third of respond-
ents thought the procedures aided retention in the study,
but most felt there was no effect. Somewhat more than
a third of respondents thought the procedures had a
positive effect on subject autonomy, but most felt there
was no discernible effect. On the other hand, almost no
respondents discerned negative effects on subjects’ rights
or retention. Hence, although the presence of subject
advocates had an impact on subjects at only a minority
of sites, when they did have an effect, it was almost always
a positive one.
Not all of the unintended consequences of the proce-
dures were positive. Reports from some research person-
nel that they contacted subject advocates when subjects
wanted to leave the study, and from some subjects that
having a subject advocate interfered with their auton-
omy, suggest that better specification of the role of sub-
ject advocate was needed. A need for better training
procedures was widely endorsed.
In addition, although sites rarely reported that having
to find subject advocates interfered with study recruit-
ment, any such interference could have had an adverse
effect on study generalizability. And though most re-
search personnel thought the effort to get subject advo-
cates was worthwhile, we cannot demonstrate clearly that
the benefits of the CATIE procedures outweighed the
costs of the efforts.
Amechanism such as the CATIE subject advocate may
be useful in future longitudinal research involving indi-
viduals with the potential for fluctuating decision-
making capacity. Precisely where such problems are
most likely to exist remains to be determined, and the
extent of fluctuation may be less in patients with schizo-
phrenia than has been thought.8 But this category might
include subjects with other psychiatric disorders, demen-
tias, and other medical disorders that affect brain func-
tioning. If researchers use such a mechanism, research
personnel will need careful training regarding procedures
to make sure that the advocate’s role is not used in un-
intended ways. Even if subject advocates directly impact
the research participation of only a minority of subjects,
they may have a positive impact by reassuring subjects,
family members, IRB members, and other interested per-
sons that subjects’ interests will be protected.
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